AstraZeneca Phase 3 Hickory Study Misses Primary Endpoint

AstraZeneca reported that its phase 3 Hickory trial for efzimfotase alfa failed to meet its primary endpoint, despite the drug having received priority review in the US. The miss raises uncertainty about the drug's regulatory path and commercial prospects. This is a company-specific clinical setback with no immediate macro-market implications.